Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis B Birth Dose for Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newborn with weight more than 2000 grams~* Born to health mothers~* No sign of congenital disease~Exclusion Criteria:~* Low birth weight newborn~* Signs and Symptoms of febrile Illness/sepsis~* Congenital Malformation~* Signs of Cyanosis~* Difficulty in breathing

- Gender: ALL
- Minimum Age: 12 Hours
- Maximum Age: 8 Months
- Healthy Volunteers: t

Study Arms:
- Intervention Arm (Type: EXPERIMENTAL): After birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the intervention group were administered GSK's ® recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs. This birth dose of hepatitis B was followed by zero dose oral polio vaccine as per hospital policy. Infants born to mother in the control group were given oral polio vaccine as per the hospital policy.
- Control Arm (Type: OTHER): In this arm of the study, after birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the control group were given oral polio vaccine as per the hospital policy. Subsequent vaccinations were administered as per the expanded program on immunization schedule in Pakistan.

Based on this trial design, predict the completion outcome and termination type (if applicable).